Eckert & Ziegler BEBIG: Half Year Results 2013 Published

Eckert & Ziegler BEBIG: Half Year Results 2013 Published

ID: 287994

(Thomson Reuters ONE) -


Regulated information

Seneffe - Belgium, August 15, 2013, Eckert & Ziegler BEBIG (Euronext: EZBG;
Reuters: EZBG.BR; Bloomberg: EZBG:BB) has announced today its financial results
for the first half of 2013.


The report including the milestones and a selection of consolidated key figures
of the first half of 2013 can be downloaded at:


www.bebig.eu > Investor Relations > Financial Reports

Eckert & Ziegler BEBIG
...Contributing to saving lives!


Eckert & Ziegler BEBIG is a European-based group, active in the medical device
sector of the healthcare industry.

Its core business is the treatment of cancer by brachytherapy, a special form of
radiotherapy. Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe and
is headquartered in Belgium. It has a production facility in Germany and
subsidiaries throughout Europe, as well as in India and in Brazil. Eckert &
Ziegler BEBIG has also established a worldwide network of distributors and
agents to support its product line.

The company's products and equipment are intended for use by oncologists,
radiologists, urologists and medical physicists.

Eckert & Ziegler BEBIG employs about 150 people. It has been listed on the
Euronext stock exchange since April 1997 (Euronext: EZBG; Reuters: EZBG.BR;
Bloomberg: EZBG: BB).

Contact:
Eckert & Ziegler BEBIG s.a.
Investor Relations
Tel: +32 (0) 64 520 808
E-mail: ir(at)bebig.eu



This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.





Source: Eckert & Ziegler BEBIG via Thomson Reuters ONE
[HUG#1723070]




Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Novartis vaccine Bexsero® approved in Australia to help protect against MenB disease, a deadly form of bacterial meningitis DGAP-News: Nordex raises full-year guidance for 2013 following a strong first half
Bereitgestellt von Benutzer: hugin
Datum: 15.08.2013 - 07:31 Uhr
Sprache: Deutsch
News-ID 287994
Anzahl Zeichen: 2178

contact information:
Town:

Seneffe



Kategorie:

Business News



Diese Pressemitteilung wurde bisher 193 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Eckert & Ziegler BEBIG: Half Year Results 2013 Published"
steht unter der journalistisch-redaktionellen Verantwortung von

Eckert & Ziegler BEBIG (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Eckert & Ziegler BEBIG



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z